# US 7,610,097 B2 · Electromagnetic stimulation in patients with osteoporosis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,610,097 B2 - Document ID: US7610097B2 - Status: Granted - Kind: B2 - Application number: 10/551,262 - Filed: 2004-04-07 - Published: 2006-09-07 - Granted: 2009-10-27 - Earliest claimed: 2003-04-10 - Inventors: Richard Markoll - Web page: https://patentgrep.com/patent/US7610097B2 ## CPC - A61N 1/326: {for promoting growth of cells, e.g. bone cells} - A61N 2/02: using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence) - A61P 19/10: for osteoporosis - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided is the combined use of pulsating electromagnetic signals and dose of Botulinum toxin to treat patients suffering from osteoporosis. Also provided is the use of electromagnetic signals generated by pulsating, impulse-modulated direct current for the treatment of osteoporosis. ## Claims ### Claim 1 Method for treating osteoporosis in a patient, comprising: exposing the patient to electromagnetic signals generated by pulsating, impulse-modulated direct current, having a frequency of 1 to 30 Hz and a field strength of 1 to 20 G; and administering Botulinum toxin to the patient, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance a bone density stimulation from the exposure of the patient to the electromagnetic signals. ### Claim 2 (depends on 1) Method according to claim 1, characterised in that the modulation form is quasi-rectangular. ### Claim 3 (depends on 1) Method according to claim 1, characterised in that the frequency is approximately 5 to 15 Hz. ### Claim 4 (depends on 1) Method according to claim 1, characterised in that the field strength is approximately 10 to 15 G. ### Claim 5 (depends on 4) Method according to claim 4, characterised in that the preferred field strength is approximately 12.5 G. ### Claim 6 (depends on 1) Method according to claim 1, characterised in that the pulses are modulated. ### Claim 7 Method for administering a treatment to a patient including administration of a neurotoxin, the method comprising: providing a pharmaceutical composition comprising Botulinum toxin; administering the Botulinum toxin to the patient intramuscularly, intravenously, or subcutaneously; and exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional, direct current, with frequency between 1 and 30 Hz and field strength, 1 to 20 G, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance a bone density stimulation from the exposure of the patient to the electromagnetic signals. ### Claim 8 (depends on 7) Method according to claim 7, characterised in that the modulation form is quasi-rectangular. ### Claim 9 (depends on 7) Method according to claim 7, characterised in that the frequency is approximately 5 to 15 Hz. ### Claim 10 (depends on 7) Method according to claim 7, characterised in that the field strength is approximately 10 to 15 G. ### Claim 11 (depends on 10) Method according to claim 10, characterised in that the field strength is approximately 12.5 G. ### Claim 12 (depends on 7) Method according to claim 7, characterised in that the pulses are modulated. ### Claim 13 (depends on 7) Method according to claim 7, characterised by using a dose of Botulinum toxin Type A in the range of 20 U to 600 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 14 (depends on 7) Method according to claim 7, characterised by using Botulinum toxin Type A in the range of 50 U to 300 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 15 (depends on 7) Method according to claim 7, characterised by using Botulinum toxin Type B in the range 1 U to 2000 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 16 (depends on 1) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 20 U to 600 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 17 (depends on 1) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 50 U to 300 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 18 (depends on 1) Method according to claim 1, characterised by using a dose of Botulinum toxin Type B in the range 1 U to 2000 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. ### Claim 19 (depends on 1) Method according to claim 1, wherein a combination of exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST®) and administering Botulinum toxin enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk. ### Claim 20 (depends on 7) Method according to claim 7, wherein a combination of exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST®) and administering Botulinum toxin enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk.